HK Stock Market Move | CUTIA-B(02487) rose more than 11% during the last trading session. The company is expected to launch three major pipeline products in 2025.

CUTIA-B (02487) rose more than 11% at the close, up 11.75% as of the time of writing, at 5.8 Hong Kong dollars, with a turnover of 1154.99 million Hong Kong dollars. The Founder pointed out that in the next 25 years, SciTech will launch three heavyweight pipeline products. The world's first external use finasteride spray, targeting the high barrier pipeline for androgenic hair loss; the world's first 4% minocycline foam for external use, targeting moderate to severe acne in adolescents aged 9 and above, with stronger safety compared to oral medications; and the fastest-progressing lidocaine dual action cream in China, providing rapid and long-lasting anesthesia, is expected to seize the compliance blue ocean market. The bank pointed out that the minoxidil series products and efficacious skincare brand OMA have commercially advanced with volume, and are currently rapidly transitioning towards multiple matrix iterations. In the next 25 years, the important milestones for the commercialization of external minocycline, external finasteride, and cream will drive strong growth in the short term, combined with long-term R&D leadership in high-barrier pipelines. It is estimated that the revenue in 2025-2026 will be about 6-10 billion yuan, with the current valuation at a low level, combined with the incremental revenues from new pipelines. Pay attention to the elastic opportunities of pipeline approvals.